Amalgamated Bank Raises Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Amalgamated Bank boosted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 50.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 84,197 shares of the company's stock after purchasing an additional 28,310 shares during the quarter. Amalgamated Bank's holdings in Hims & Hers Health were worth $2,488,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of HIMS. SlateStone Wealth LLC boosted its position in shares of Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock worth $257,000 after purchasing an additional 413 shares in the last quarter. Blume Capital Management Inc. boosted its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after acquiring an additional 628 shares during the last quarter. Cim LLC grew its position in Hims & Hers Health by 1.0% during the 4th quarter. Cim LLC now owns 71,869 shares of the company's stock worth $1,738,000 after purchasing an additional 694 shares during the last quarter. Finally, Harbour Investments Inc. increased its stake in Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on HIMS. Wall Street Zen raised Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Sunday, June 15th. Truist Financial set a $45.00 price objective on Hims & Hers Health in a report on Tuesday, June 24th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Finally, Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus price target of $39.58.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 17,102 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the sale, the insider owned 278,654 shares of the company's stock, valued at approximately $16,649,576.50. The trade was a 5.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 8,485 shares of Hims & Hers Health stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $506,978.75. Following the completion of the sale, the insider owned 712 shares in the company, valued at approximately $42,542. This trade represents a 92.26% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 692,006 shares of company stock worth $34,857,872. 13.71% of the stock is currently owned by company insiders.

Hims & Hers Health Trading Up 0.8%

Hims & Hers Health stock traded up $0.36 during mid-day trading on Monday, hitting $48.34. The company had a trading volume of 27,287,587 shares, compared to its average volume of 23,484,617. The company has a market capitalization of $10.82 billion, a price-to-earnings ratio of 70.06, a P/E/G ratio of 1.76 and a beta of 2.02. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The company's fifty day moving average is $52.23 and its 200-day moving average is $40.38.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same period in the prior year, the firm posted $0.05 earnings per share. The firm's quarterly revenue was up 110.7% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.